Your browser doesn't support javascript.
loading
PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer.
Fujita, T; Doihara, H; Kawasaki, K; Takabatake, D; Takahashi, H; Washio, K; Tsukuda, K; Ogasawara, Y; Shimizu, N.
Affiliation
  • Fujita T; Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, 700-8558 Okayama, Japan. cqs03255@nifty.com
Br J Cancer ; 94(2): 247-52, 2006 Jan 30.
Article in En | MEDLINE | ID: mdl-16404430
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Biomarkers, Tumor / Receptor, ErbB-2 / PTEN Phosphohydrolase / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Br J Cancer Year: 2006 Document type: Article Affiliation country: Japón Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Biomarkers, Tumor / Receptor, ErbB-2 / PTEN Phosphohydrolase / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Br J Cancer Year: 2006 Document type: Article Affiliation country: Japón Country of publication: Reino Unido